Life expectancy increases among treated HIV-positive individuals in US and Canada

December 18, 2013

A 20-year-old HIV-positive adult on antiretroviral therapy (ART) in the U.S. or Canada may be expected to live into their early 70's, a life expectancy approaching that of the general population, according to results published December 18, 2013, in the open access journal PLOS ONE by Hasina Samji and colleagues from the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) and the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

The life expectancies of nearly 23,000 individuals on ART were calculated based on in the early to mid-2000s. Participants in the study were from the NA-ACCORD and aged 20 years or older. Changes in life expectancy from 2000 to 2007 among HIV-positive individuals were then evaluated by selected sociodemographic and clinical characteristics, such as drug use history and immune cell counts

The authors found that life expectancy at age 20 increased from 36.1 to 51.4 years from 2000-2002 to 2006-2007. Men and women had comparable life expectancies in all periods except the last (2006-2007). Life expectancy was lower for individuals with a history of injection drug use, those who were non-white, and those who initiated ART with low CD4 count (a count of cells that activate the immune response) compared to those who started at a higher count. The results of this study indicate increasing longevity for individuals living with HIV in the U.S. and Canada and contribute to the growing evidence that HIV-positive people on ART have approaching those in general populations.

More information: Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, et al. (2013) Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE 8(12): e81355. DOI: 10.1371/journal.pone.0081355

Related Stories

Food insecurity linked to HIV-treated drug users' deaths

May 31, 2013

Food insecurity increases the risk of death among injection drug users living with HIV/AIDS even when they are receiving life-prolonging antiretroviral therapy (ART), according to a new study involving Simon Fraser University.

Recommended for you

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.